people
  • Overview
  • Grant Central
    Find funding & collaboration opportunities, and coordinate proposal development.
  • Medvane
    View biomedical research & publication trends within the Harvard community.
  • Profiles
    Contact, publication, and social network information about Harvard faculty and fellows.
  • Research Navigators
    Scientific liaisons who facilitate clinical and translational research.
learning
resources

Medvane

The present state and historical trends of biomedical research in the Harvard community.

Determinant of HIV-1 mutational escape from cytotoxic T lymphocytes. J Exp Med 2003

Division of Infectious Diseases, 37-121 CHS, UCLA Medical Center, 10833 LeConte Ave., Los Angeles, CA 90095, USA. oyang@mednet.ucla.edu
CD8+ class I-restricted cytotoxic T lymphocytes (CTLs) usually incompletely suppress HIV-1 in vivo, and while analogous partial suppression induces antiretroviral drug-resistance mutations, epitope escape mutations are inconsistently observed. However, escape mutation depends on the net balance of selective pressure and mutational fitness costs, which are poorly understood and difficult to study in vivo. Here we used a controlled in vitro system to evaluate the ability of HIV-1 to escape from CTL clones, finding that virus replicating under selective pressure rapidly can develop phenotypic resistance associated with genotypic changes. Escape varied between clones recognizing the same Gag epitope or different Gag and RT epitopes, indicating the influence of the T cell receptor on pressure and fitness costs. Gag and RT escape mutations were monoclonal intra-epitope substitutions, indicating limitation by fitness constraints in structural proteins. In contrast, escape from Nef-specific CTL was more rapid and consistent, marked by a polyclonal mixture of epitope point mutations and upstream frameshifts. We conclude that incomplete viral suppression by CTL can result in rapid emergence of immune escape, but the likelihood is strongly determined by factors influencing the fitness costs of the particular epitope targeted and the ability of responding CTL to recognize specific epitope variants.
See PubMed record in a new window